Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis

Osteoporosis International

Volumn 24, Issue 4, 2013, Pages 1491-1502

  Strom O ^a   Jonsson B ^b   Kanis, J A ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Cost effectiveness; Denosumab; Fracture; FRAX; Osteoporosis

Indexed keywords

ALENDRONIC ACID; DENOSUMAB; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE;

ADULT; AGED; ALGORITHM; ARTICLE; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FEMALE; FOREARM FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT; SPINE FRACTURE; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; ALENDRONATE; ALGORITHMS; ANTIBODIES, MONOCLONAL, HUMANIZED; BONE DENSITY CONSERVATION AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; ETIDRONIC ACID; FEMALE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; MODELS, ECONOMETRIC; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; QUALITY OF LIFE; RANK LIGAND; RISK ASSESSMENT; THIOPHENES;

EID: 84876473359     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-012-2115-6     Document Type: Article

References (70)

1. Kanis J (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK
2. Kanis JA et al (2008) FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385-397
3. Kanis JA et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18(8):1033-1046
4. Fujiwara S et al (2008) Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 19(4):429-435
5. Association Suisse contre l'Osteoporose (2011) Osteoporose: Recommandations 2010. Bern
6. Neuprez A et al (2009) A FRAX model for the assessment of fracture probability in Belgium. Rev Med Liege 64(12):612-619
7. Grossman JM et al (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken) 62:15-26
8. NOF (2008) Physician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
9. Socialstyrelsen (2010) Nationella riktlinjer för rörelseorganens sjukdomar 2012. Osteoporos, artros, inflammatorisk ryggsjukdom och ankyloserande spondylit, psoriasisartrit och reumatoid artrit. Stöd för styrning och ledning. 1-116. Publicerad
10. Papaioannou A et al (2010) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. Cmaj 182(17):1864-1873
11. U.S. Preventive Services Task Force (2011) Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med 154(5):356-364
12. Kanis JA et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19(4):399-428
13. Kurth AA, Pfeilschifter J (2007) Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German Guidelines Update 2006. Orthopade 36(7):683-690, quiz 691
14. Compston J et al (2009) Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas 62(2):105-108
15. National Osteoporosis Foundation (2008) Clinician's guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC
16. National Institute for Health and Clinical Excellence (2010) Final appraisal determination 160. Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London
17. National Institute for Health and Clinical Excellence (2010) Final appraisal determination 161. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. National Institute for Health and Clinical Excellence, London
18. National Institute for Health and Clinical Excellence (2010) Technology appraisals TA204: Osteoporotic fractures - denosumab. Accessed 5 June 2011; http://guidance.nice.org.uk/TA204
19. Kanis J et al (2010) An evaluation of the NICE guidance for the prevention of osteoporotic fragility fractures in postmenopausal women. Arch Osteoporos. doi: 10.1007/s11657-010-0045-5
20. Kanis JA et al (2008) Case finding for the management of osteoporosis with FRAX - assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395-1408, Erratum published 2009 Osteoporos Int 20, 499-502
21. Borgstrom F et al (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int 21(3):495-505
22. Borgstrom F et al (2010) The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis. Osteoporos Int 21(2):339-349
23. Cummings SR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756-765
24. Li L et al (2010) Non-persistence to anti-osteoporosis medications in the UK using the general practice research database (GPRD) Rheumatology 49 Supplement 1 (OP54)
25. Landfeldt E et al (2012) Adherence to treatment of primary osteoporosis and its association to fractures-the Swedish Adherence Register Analysis (SARA). Osteoporos Int 23(2):433-434
26. Jonsson B et al (2010) Cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis. Osteoporos Int 22(3):967-982
27. Strom O et al (2009) Incorporating adherence into health economic modelling of osteoporosis. Osteoporos Int 20(1):23-34
28. NICE (2008) Guide to the methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 18 Jan 2012
29. Strom O et al (2007) Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European countries - an economic evaluation based on the fracture intervention trial. Osteoporos Int 18(8):1047-1061
30. Kanis J et al (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6(29):1-146
31. Stevenson M et al (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005 Jun;9(22):1-160
32. Strom O et al (2010) FRAX and its applications in health economics - cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 47(2):430-437
33. Seeley DG et al (1991) Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group. Ann Intern Med 115(11):837-842
34. National Institute for Health and Clinical Excellence (2008) Systematic reviews of clinical effectiveness prepared for the guideline osteoporosis: "assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk". http://www.nice.org.uk/guidance/index.jsp? action=byID&o=11621. Accessed 12 March 2011
35. Freemantle N et al (2011) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317-326
36. Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide. Accessed 13 May 2008; http://www.nice.org.uk/page. aspx?o=370643
37. Reginster JY et al (2009) Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years. Bone 45(6):1059-1064
38. Singer BR et al (1998) Epidemiology of fractures in 15,000 adults: the influence of age and gender. J Bone Joint Surg Br 80(2):243-248
39. de Lusignan S et al (2006) Using computers to identify non-compliant people at increased risk of osteoporotic fractures in general practice: a cross-sectional study. Osteoporos Int 17(12):1808-1814
40. Kanis JA et al (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11(7):iii-iv, ix-xi, 1-231
41. National Statistics: The official UK statistics site. www.statistics.gov.uk. Accessed 14 January 2011
42. Johnell O et al (2004) Mortality after osteoporotic fractures. Osteoporos Int 15(1):38-42
43. Stevenson M, Davis S, Kanis J (2006) The hospitalization costs and outpatient costs of fragility fractures. Women's Health Med 4:149-151
44. Kanis JA et al (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12(5):417-427
45. Borgstrom F et al (2006) Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos Int 17(5):637-650
46. Ström O et al (2008) Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden. Acta Orthop 79(2):269-280
47. Curtis L (2010) Unit Costs of Health and Social Care. http://www.pssru.ac.uk/pdf/uc/uc2010/uc2010.pdf. Accessed 1 Dec 2010
48. Jonsson B et al (1996) Cost-effectiveness of fracture prevention in established osteoporosis. Scand J Rheumatol Suppl 103:30-38
49. Swedish National Inpatient Register and Causes of Death Register, The Swedish National Board of Health Centre - The Epidemiological Centre, http://www.sos.se/epc/epceng.htm. Accessed 1 Dec 2011
50. Kanis JA et al (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15(2):108-112
51. Bliuc D et al (2009) Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Jama 301(5):513-521
52. Kanis JA et al (2003) The components of excess mortality after hip fracture. Bone 32(5):468-473
53. Borgstrom F et al (2006) An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting: based on the results of the SOTI and TROPOS trials. Osteoporos Int 17(12):1781-1793
54. Kanis JA et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42(1):4-15
55. Kind P et al (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. Br Med J 316(7133):736-741
56. Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35(11):1095-1108
57. Stevenson M, Davis S (2006) Analyses of the cost-effectiveness of pooled alendronate and risedronate, compared with strontium ranelate, raloxifene, etidronate and teriparatide (NICE). The University of Sheffield, School of Health and Related Research, Sheffield
58. Borgstrom F et al (2004) Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study. PharmacoEconomics 22(17):1153-1165
59. Kanis JA et al (2008) Case finding for the management of osteoporosis with FRAX((R))-assessment and intervention thresholds for the UK. Osteoporos Int 19(10):1395-1408
60. Cummings SR et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. Jama 280(24):2077-2082
61. Scotland G et al (2011) Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. PharmacoEconomics 29(11):951-961
62. van Staa TP et al (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39(12):1383-1389
63. Kanis JA et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16(7):737-742
64. Kanis JA et al (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22(9):2395-2411
65. Delmas PD et al (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33(4):522-532
66. Klotzbuecher CM et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15(4):721-739
67. Kanis JA et al (2011) A reappraisal of generic bisphosphonates in osteoporosis. Osteoporos Int
68. McCloskey EV et al (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy - additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20(5):811-817
69. Kanis JA et al (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44(6):1049-1054
70. McCloskey EV, Johansson H, Oden A, (2012) Denosumab reduces the risk of all osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX®. J Bone Miner Res. doi: 10.1002/jbmr.1606